ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Up 44.9% in August

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,420,000 shares, an increase of 44.9% from the August 15th total of 1,670,000 shares. Based on an average daily volume of 299,400 shares, the short-interest ratio is presently 8.1 days.

Analysts Set New Price Targets

Several research firms recently weighed in on ANIP. Truist Financial reissued a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.75.

Insider Activity

In other news, COO Muthusamy Shanmugam sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, June 21st. The stock was sold at an average price of $58.90, for a total value of $1,178,000.00. Following the transaction, the chief operating officer now owns 682,620 shares in the company, valued at approximately $40,206,318. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 65,757 shares of company stock worth $4,075,585. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $228,000. The Manufacturers Life Insurance Company increased its position in ANI Pharmaceuticals by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,498 shares of the specialty pharmaceutical company’s stock valued at $605,000 after buying an additional 1,211 shares in the last quarter. Millennium Management LLC increased its position in ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after buying an additional 209,272 shares in the last quarter. Maverick Capital Ltd. increased its position in ANI Pharmaceuticals by 302.1% in the 2nd quarter. Maverick Capital Ltd. now owns 18,536 shares of the specialty pharmaceutical company’s stock valued at $1,180,000 after buying an additional 13,926 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C increased its position in ANI Pharmaceuticals by 11.0% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,138 shares of the specialty pharmaceutical company’s stock valued at $327,000 after buying an additional 511 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $58.51 on Monday. The stock has a 50-day moving average price of $61.39 and a 200-day moving average price of $63.93. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The firm has a market cap of $1.23 billion, a PE ratio of 36.57 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. During the same period last year, the company posted $1.06 EPS. The business’s quarterly revenue was up 18.5% on a year-over-year basis. As a group, equities research analysts expect that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.